LRMR

Larimar Therapeutics, Inc.

3.50 USD

Last updated Nov 29, 12:33 UTC

Yesterday HIGH

$3.56

Yesterday LOW

$3.31

52w HIGH

$6.85

52w LOW

$2.18

EPS

-0.21

PE

-16.67

Next Earnings

Mar 12, 2024

Overview News Government Trades

Larimar Therapeutics, Inc. stock is up 19.86% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 November’s closed higher than October. 100% of analysts rate it a buy.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Cynwyd , United States Of America

Website

larimartx.com

Benzinga Newsdesk

Mon May 15, 2023

Larimar Therapeutics Q1 EPS $(0.15) Beats $(0.25) Estimate

Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.25) by 40 percent. This is a 69.39 percent increase over losses of $(0.49) per share from
Benzinga Newsdesk

Mon May 15, 2023

Larimar Therapeutics Announced Preliminary Topline Data From 25mg Cohort Of Its Phase 2 Trial Of CTI-1601 For Friedreich's Ataxia; CTI-601 Was Generally Well Tolerated And Showed Increases In Frataxin Levels From Baseline Compared To Placebo
richadhand@benzinga.com

Wed Mar 15, 2023

Guggenheim Reiterates Buy on Larimar Therapeutics, Maintains $12 Price Target

Guggenheim analyst Yatin Suneja reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Buy and maintains $12 price target.
Benzinga Newsdesk

Tue Mar 14, 2023

Larimar Therapeutics Q4 EPS $(0.21) Beats $(0.37) Estimate; Cash & Investments Of $118.4M Provides Projected Cash Runway Into 2H 2024

Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.37) by 43.24 percent. This is a 58 percent increase over losses of $(0.50) per share from
Benzinga Newsdesk

Tue Dec 13, 2022

Citigroup Initiates Coverage On Larimar Therapeutics with Neutral Rating, Announces Price Target of $4

Citigroup analyst Samantha Semenkow initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Neutral rating and announces Price Target of $4.
Benzinga Newsdesk

Thu Nov 10, 2022

Larimar Therapeutics Q3 EPS $(0.37) Up From $(0.92) YoY

Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.37) per share. This is a 59.78 percent increase over losses of $(0.92) per share from the same period last year.
Benzinga Newsdesk

Thu Oct 20, 2022

Larimar Therapeutics Announces Issuance Of U.S. Patent Providing Composition Of Matter Protection For CTI-1601

Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the issuance of U.S. Patent
Benzinga Insights

Wed Oct 19, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022

Upgrades
Benzinga Newsdesk

Wed Oct 19, 2022

Guggenheim Initiates Coverage On Larimar Therapeutics with Buy Rating, Announces Price Target of $12

Guggenheim analyst Yatin Suneja initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Buy rating and announces Price Target of $12.
Lisa Levin

Wed Sep 21, 2022

$35 Million Bet On This Penny Stock? Check Out These 3 Stocks Under $4 Insiders Are Buying

The Dow Jones dropped by more than 300 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.